(Reuters) -The Centers for Disease Control and Prevention’s vaccine advisory committee is set to meet for the first time since Health Secretary Robert F. Kennedy Jr. fired the entire panel and named eight new members, half of whom have advocated against vaccines.
The meeting, scheduled for June 25-26, will review existing data and vote on RSV and influenza vaccines, along with thimerosal, a preservative used in vials of medicines and vaccines.
Below are some of the companies that make the vaccines that will be discussed at the meeting, according to the final agenda published on the CDC’s website.
FLU VACCINES
Sanofi
Fluzone – The quadrivalent influenza vaccine was approved in 2013 for patients aged six months and older.
Flublok – Approved in 2016 for adults aged 18 and older, replacing the trivalent version licensed in 2013 by offering protection against four influenza strains.
Sanofi reported U.S. sales of $1.66 billion for influenza vaccines in 2024.
AstraZeneca/MedImmune
FluMist – FDA approved AstraZeneca and partner MedImmune’s nasal spray influenza vaccine in September 2024 for self-administration by adults up to 49 years of age, or by a parent/caregiver to individuals aged 2-17 years. The vaccine generated sales of about $258 million in 2024.
CSL Seqirus, part of Australia-based biotech firm CSL Ltd
FlucelVax – The FDA approved the cell-based influenza vaccine in October 2021 for people aged six months and older.
Afluria – The egg-based influenza vaccine was approved in October 2018 for people aged six months and older.
Fluad – The adjuvanted influenza vaccine was approved by the FDA in February 2020 for people aged six months and older.
The three vaccines combined brought in sales of $1.72 billion in 2024
RSV VACCINES
Sanofi/AstraZeneca
Nirsevimab (Beyfortus) – The FDA approved the antibody, branded as Beyfortus, in 2023 to prevent respiratory syncytial virus (RSV) infections in infants.
Sanofi reported U.S. sales of $1.24 billion for the vaccine in 2024.
Merck ()
Clesrovimab (Enflonsia) – The company gained approval for its RSV-preventing antibody, branded as Enflonsia, in June 2025. The antibody is designed for infants up to one-year olds during their first RSV season, with shipments planned for the 2025-2026 season.
MMR
GSK
Priorix – Approved by the FDA for the prevention of measles, mumps, and rubella (MMR) in individuals aged one year and older. It can be administered in two doses or as a second shot following a prior MMR vaccination. GSK reported global sales of $439.96 million for the vaccine in 2024.
COVID-19 VACCINES
MODERNA
mNEXSPIKE – The next-generation COVID-19 vaccine was approved for aged 65 and above in May 2025.
Spikevax, Moderna’s first COVID-19 vaccine, received its initial FDA approval in January 2022. Spikevax brought in total sales of $1.8 billion in 2024.
Pfizer/BioNTech
Comirnaty – The COVID-19 vaccine was approved by the FDA in August 2021 for people aged 16 years and older. It generated sales of $5.35 billion in 2024.
Novavax
Nuvaxovid – The protein-based COVID-19 vaccine was approvedby FDA in May 2025 for people aged 65 and older, following nearly five years of regulatory delays and financial uncertainty. The vaccine, Novavax’s sole commercial product, generated $682 million in total revenue for 2024, which includes licensing and royalties.
(Reporting by Siddhi Mahatole and Padmanabhan Ananthan in Bengaluru; Editing by Sriraj Kalluvila)
Comments